Guggenheim raises Elevance Health target to USD 460: Elevance Health stock pre-market at EUR 378.15
Published on 10/13/2026 at 08:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Elevance Health was EUR 378.15 at Lang & Schwarz pre-market.
- Guggenheim raised its price target to USD 460 from USD 455.
- Elevance Health plans to discuss third-quarter results on October 21, 2026.
Guggenheim raised its price target for Elevance Health to USD 460 from USD 455 on October 12, 2026, while maintaining a Buy rating, according to Investing.com. Elevance Health stock was EUR 378.15 at Lang & Schwarz at 8:23 a.m. CEST on October 13, 2026.
Pre-market indication
The Lang & Schwarz bid was EUR 376.40 and the ask was EUR 379.90. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Elevance Health stock.
What matters today
Elevance Health is scheduled to hold a conference call on October 21, 2026, to discuss its third-quarter results, according to FinancialContent. The next round-number level is EUR 400.00. Guggenheim’s October 12, 2026, target is USD 460, up from USD 455, according to Investing.com.
Market context: Market report S&P 500.
